Clinical Trials

120 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

175 enrolled 16 charts

Phase 1/2 Active not recruiting

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT05182385 2025-07-25

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

30 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05735717 2025-07-24

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CNSClassical hematologyLymphoidOther hematologic neoplasm

70 enrolled

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT04827745 2025-07-03

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Phase 2 Completed

2 enrolled

Phase 1 Active not recruiting

Leukemia, Biphenotypic, Acute, Neoplasm, Residual

NCT03241940 2025-06-29

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

33 enrolled

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07021677 2025-06-15

DARA_T_ALL

18 enrolled

Phase 2 Active not recruiting

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

69 enrolled 12 charts

Leukemia, Hairy Cell, Neoplasm, Residual

NCT07003737 2025-06-04

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

114 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

MyeloidOther hematologic neoplasm

8 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT02988466 2025-05-28

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Phase 2 Completed

78 enrolled 16 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Bone Marrow Failure Disorders, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Follicular, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Neoplasm, Residual, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT06718244 2025-05-23

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

20 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Phase 1/2 Terminated

4 enrolled 7 charts

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04506086 2025-05-18

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 4 Terminated

10 enrolled 12 charts

Leukemia, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05959720 2025-05-07

BRALLA

Recruiting

180 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03038230 2025-04-06

MCLA-117 in Acute Myelogenous Leukemia

80 enrolled

Recurrence, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06885476 2025-03-20

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

22 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06886074 2025-03-20

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

30 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01743807 2025-01-27

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

4 enrolled 6 charts

Recurrence, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04466059 2024-12-17

BELUGA

Recruiting

25,000 enrolled

Leukemia, Lymphoma, Neoplasm, Residual, Hematologic Neoplasms

NCT04310592 2024-12-12

CYNK001AML01

27 enrolled

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT05904106 2024-12-02

VINCENT

146 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Phase 1 Completed

20 enrolled

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

MyeloidOther hematologic neoplasm

67 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04545333 2024-08-01

The clonoSEQ® Watch Registry

Terminated

465 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06301425 2024-07-10

MRD Response-adapted Allo-HSCT for Adverse-risk AML

178 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04920188 2024-07-05

Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

Terminated

10 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03192397 2024-05-29

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

35 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT06090786 2024-04-10

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Phase NA Not yet recruiting

225 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03982992 2024-03-12

DLI-TARGET

Phase 2 Withdrawn

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04785547 2024-01-16

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Phase 2 Terminated

3 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06125106 2023-11-09

Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab

Phase 1 Unknown

31 enrolled